Default company panoramic image

CompleGen, Inc.

CompleGen is a drug discovery company that specializes in allosteric drugs in oncology, inflammation and respiratory diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, USA
  • Currency USD
  • Employees 10

Company Summary

CompleGen’s unique discovery platform, XenoGene Technology™, has generated a rich pipeline of small molecule therapeutics that are at various stages of preclinical development with proof of relevance in animal models. We have ongoing partnering discussions with pharma for our preclinical candidates in KRas cancers and inflammatory diseases. We leverage our core XenoGene technology in discovery collaborations, e.g., Boehringer Ingelheim.


  • Default avatar
    John Thomas Swindle
    President & CEO

    Dr. Swindle is a co-founder of CompleGen and is responsible for inventing its core XenoGene technology. Dr. Swindle's expertise in the manipulation of genes in yeast and parasites is widely recognized. Before starting CompleGen he was a member of the Infectious Disease Research Institute and the Seattle Biomedical Research Institute. Before returning to Seattle he was a Professor of Microbiology and Immunology at the University of Tennessee.

  • Default avatar
    Pauline Gee
    Vice President, Business Development

    Dr. Gee executed technology and chemical library licensing and merger agreements prior to joining CompleGen. Amongst several entrepreneurial activities, she was President & CEO of Xenometrix, Inc., a public company that won two Deloitte & Touche Fast 50 awards. Formerly she held executive positions at Sciona, MDS Pharma Services and Discovery Partners International. She was also awarded the PolyPops Award for innovative assay development.